Showing 141 - 160 results of 66,048 for search '(( i values increased ) OR ((( c larger decrease ) OR ( ((c larger) OR (a large)) decrease ))))', query time: 1.81s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150

    Dehydration-Rehydration Studies on Polytypes of Chloride and Nitrate Layered Double Hydroxides of Nordstrandite and Bayerite: a Comparative Study by Kavitha Venkataraman (12043316)

    Published 2022
    “…Dehydration of nitrate intercalated LDH, which proceeds from an orthorhombic symmetry to a monoclinic symmetry with no decrease in the interlayer spacing, is attributed to sliding of the hydroxyl layers in the <i>ab</i>-plane due to the increase in the β value. …”
  11. 151

    Dehydration-Rehydration Studies on Polytypes of Chloride and Nitrate Layered Double Hydroxides of Nordstrandite and Bayerite: a Comparative Study by Kavitha Venkataraman (12043316)

    Published 2022
    “…Dehydration of nitrate intercalated LDH, which proceeds from an orthorhombic symmetry to a monoclinic symmetry with no decrease in the interlayer spacing, is attributed to sliding of the hydroxyl layers in the <i>ab</i>-plane due to the increase in the β value. …”
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  17. 157

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  18. 158
  19. 159
  20. 160